Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: Effect of FCGR polymorphism on the occurrence of late-onset neutropenia and flare-free survival in rheumatic patients treated with rituximab

Fig. 4

Kaplan-Meier estimates of the percentages of patients without flare from the time of rituximab therapy in total and by groups of late-onset neutropenia (LON) occurrence and genotypic polymorphism. Depicted are flare-free survival estimates for 61 patients after treatment with rituximab through the observation period (53 flares) (a) and during the 12-month follow-up (34 flares) in the groups by occurrence of LON (b), by FCGR3A 158V/F polymorphism (c), and by B-cell-activating factor (BAFF) −871C/T polymorphism (d)

Back to article page